Physician profile
George E Mansour
NPI 1881636082
$5,026.03
in general payments reported to CMS, 2019-2025
31 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $354 · 2021: $671 · 2022: $1,057 · 2023: $800 · 2024: $975 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,050.98 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $673.37 | 2021-2024 | |
| Amgen INC. | $390.16 | 2019-2022 | |
| Pfizer INC. | $345.15 | 2019-2024 | |
| Allergan, INC. | $339.36 | 2019-2020 | |
| Novo Nordisk INC | $321.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $312.38 | 2020-2024 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $295.33 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $199.37 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $171.68 | 2019-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $140.93 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $119.80 | 2022-2024 | Quviviq |
| Abbott Laboratories | $81.67 | 2020-2024 | Freestyle Libre 3 |
| Phadia US INC. | $70.01 | 2020-2024 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $69.57 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $60.43 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $49.77 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.91 | 2022 | |
| Ardelyx, INC. | $33.48 | 2024 | Ibsrela |
| Averitas Pharma INC. | $33.21 | 2025 | Qutenza |
| Philips North America LLC | $26.53 | 2022 | |
| Esperion Therapeutics, INC. | $24.44 | 2021 | |
| Edwards Lifesciences Corporation | $24.33 | 2020 | |
| Smith+Nephew, INC. | $21.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.79 | 2025 | Eohilia |
| Alnylam Pharmaceuticals INC. | $20.43 | 2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.25 | 2019 | |
| Inspire Medical Systems, INC. | $19.65 | 2024 | Inspire |
| Clarus Therapeutics INC. | $17.57 | 2021 | |
| Lucid Diagnostics INC. | $15.30 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.